RSV Vaccine

About VLP Biotech

VLP Biotech is a private, preclinical-stage biotech firm specializing in vaccine development for infectious diseases using its proprietary recombinant protein platform. The company operates a service-based model for custom antibody production while advancing its own vaccine candidates through early-stage government-funded grants. With a lean structure, it has secured non-dilutive funding from entities like Leidos and the U.S. government's SBIR/STTR programs to fuel its R&D efforts. Its strategy combines contract services with internal pipeline development to address significant unmet medical needs.

About Auro Vaccines

Auro Vaccines, a wholly-owned subsidiary of Aurobindo Pharma USA, is a clinical-stage biotech focused on a fundamental new approach to vaccine design. Its proprietary PBS Vax™ platform allows precise 'tuning' of immune responses to overcome the shortcomings of current DNA and classic prophylactic vaccines. The company has established a pipeline targeting high-unmet-need areas like HPV-associated cervical dysplasia, SARS-CoV-2, Chikungunya, and RSV, and maintains significant partnerships with entities like Emergent BioSolutions and CEPI for filovirus and other outbreak pathogen vaccines.

About Artificial Cell Technologies

Artificial Cell Technologies is pioneering a novel, fully synthetic vaccine manufacturing platform using Layer-by-Layer (LbL) polypeptide nanofilms. This technology aims to produce temperature-stable, multi-valent vaccines rapidly and at low cost, enabling decentralized production closer to patient populations. The company's initial pipeline targets Respiratory Syncytial Virus (RSV) and malaria, with a malaria vaccine candidate historically noted as preparing for Phase 1 trials. ACT's approach seeks to disrupt traditional vaccine supply chains, particularly for the developing world.

About Calder Biosciences

Calder Biosciences is a private, preclinical-stage biotech applying its novel 3D-Vaxlock™ protein engineering platform to develop best-in-class vaccines. The platform introduces targeted, covalent dityrosine crosslinks to 'lock' viral immunogens in their most potent prefusion shape, aiming to elicit stronger and more protective immune responses. Initial pipeline targets include RSV and a universal influenza vaccine, with the goal of improving efficacy, durability, and thermostability over existing options. The company emphasizes a de-risked approach by engineering solutions for well-characterized viral targets rather than pursuing de novo discovery.

About Recbio Technology

A Chinese vaccine innovator with proprietary adjuvant and protein engineering platforms, advancing late-stage HPV and shingles vaccines.

About Sinovac Biotech

Sinovac Biotech's mission is to supply vaccines to eliminate human infectious diseases worldwide. Its key achievement was the development and global distribution of CoronaVac, one of the most widely administered COVID-19 vaccines, which solidified its international standing and showcased its integrated manufacturing model. The company's strategy is anchored in its core inactivated vaccine technology platform, with a focus on expanding its pipeline for both endemic and pandemic threats while pursuing commercial partnerships in emerging markets. Financially, it faces the challenge of transitioning from peak pandemic revenue to a sustainable portfolio-driven growth model.

Therapeutic Areas

Other Respiratory Syncytial Virus infection Drugs